Correction: Phase 2 study of pembrolizumab in patients with advanced rare cancers

• Luc Dirix,
• Eyal Fenig,
• Rodrigo Munhoz,
• Elena Benincasa,
• Sarah Flaskett,
• Josh Reed,
• Arne Engelsberg

Affiliations

Luc Dirix

Aff5 Saint-Augustinus Hospital Antwerp Belgium

Eyal Fenig

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Rodrigo Munhoz

Oncology Center, Hospital Sírio-Libanês, São Paulo, São Paulo, Brazil

Elena Benincasa

Medical Affairs, Merck KGaA, Darmstadt, Hessen, Germany

Sarah Flaskett

Regional Clinical Operations, Merck Serono, Feltham, Middlesex, UK

Josh Reed

Medical Affairs, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA

Arne Engelsberg

Pfizer Oncology, Pfizer Pharma, Berlin, Germany